Category: California Institute for Quantitative Biosciences

Slicing the Pie: Entity Formation and the Division of Equity

Slicing the Pie: Entity Formation and the Division of Equity

qed@qb3 - UCB Friday, March 5, 2010 12:00 to 1:00 pm Stanley Hall Room 621

Matt Kirmayer will lead a discussion of the issues relating to forming an entity, seeding it with the assets and IP to be successful, and avoiding the potential pitfalls  when dividing up the equity among the founders.

Matt Kirmayer is a member in the Corporate practice. His practice is focused on the representation of emerging technology companies, venture capital and private equity funds and institutional investors.  Matt represents clients in many industries, such as multimedia, wireless technologies, networking, internet infrastructure and security, nanotechnology, life sciences and medical devices. He also represents NY Money Center Banks and institutional investors in capital market transactions. Prior to joining Mintz Levin, Matt was a partner at a San Francisco area law firm. Matt began his career in New York City handling securities offerings and merger and acquisition transactions. Matt is admitted to practice law in California and New York.  He received a J.D. from Rutgers University and an LL.M. from New York University School of Law.

Lunch provided, but space is limited so please reserve a seat here.

http://qb3.org/services/qed-qb3/?searchterm=qed

...But what do I know? Lessons learned from living through a couple of spin-out companies

...But what do I know? Lessons learned from living through a couple of spin-out companies

qed@qb3 UCSF Thursday, March 4, 2010 12:00 to 1:00 pm Byers Hall Room 212

There are many lessons to be learned in the formation of spinouts. Tom will walk through his experiences going from an academic setting to a spinout company and what he has learned from this and a couple of other companies that he has been close to (Avantome, TrueMaterials, Boreal Genomics)

Tom Willis is the CEO of MLC Dx Inc. a VC backed company dedicated to the commercialization of molecular diagnostic tests. Prior to founding MLC, Tom has been an entrepreneur in the biotech industry for the past decade. After receiving his Ph.D. in physics from Stanford University, he joined the Stanford Genome Technology Center (SGTC) to work on DNA sequence analysis technologies. He held several positions at the SGTC including Associate Director in charge of technology development. While at SGTC, he co-invented the Molecular Inversion Probe technology for high throughput genotyping. In 2001, he co-founded ParAllele BioScience to develop and commercialize this technology. As its founding CEO, he led ParAllele through two rounds of VC financing a grew the company to over 80 employees. In 2005 ParAllele was acquired by Affymetrix at which time Tom served in several management positions at Affymetrix. He left in 2007 to pursue new startup opportunities. In addition to his role at MLC, Tom serves on the boards of SpinX Technologies and Boreal Genomics

Lunch provided, but space is limited so please reserve a seat at http://www.acteva.com/booking.cfm?bevaID=198455

http://qb3.org/services/qed-qb3/?searchterm=qed

Risk Management and Insurance Primer for Life Science Companies

Risk Management and Insurance Primer for Life Science Companies

qed@qb3 - Special Event Tuesday, February 23, 2010 12:00 to 1:00 pm Byers Hall Room 212

In this discussion we will touch on the various aspects and stages of Risk Management and Insurance for Life Science Companies from start-up, through clinical trials to product commercialization.  The primer will touch on all aspects of insurance from workers' compensation, property and general liability, to clinical trials, international, directors and officers and more.

Kevin Mirsky is a Principal of Saylor & Hill Co. and has been with the firm since 1991. Kevin leads Saylor & Hill Co.'s Technology and Life Science Practice in the Bay Area, providing Risk Assessment and Insurance Brokerage services to mid- and large-size clients. He has expertise in multi-national clinical trials, medical device and pharmaceutical products as well as software, hardware and web-based businesses. Kevin is active in the community, and is a member of BayBio.

Lunch provided, but space is limited so please reserve a seat at http://www.acteva.com/booking.cfm?bevaID=198053

Building, Compensating & Motivating a Leadership Team

Building, Compensating & Motivating a Leadership Team

qed@qb3 - UCSF Thursday, February 4, 2010 12:00 to 1:00 pm Byers Hall Room 212

 One of the most critical factors for a company's success is building an excellent team, but finding, recruiting, compensating, and ultimately motivating the best people is extremely challenging.  Chris McKinley and Michael Ballenger bring decades of HR and executive recruitment experience to this subject and will share their insights and advice in this seminar.

Christine McKinley has 30 years experience working in entrepreneurial, high growth biotech and medical companies. Prior to founding Round One Resources, she was Sr.VP of Human Resources at Cell Genesys, responsible for strategic and operational HR initiatives, involving extensive staffing of a manufacturing facility, expansion of process development, manufacturing and clinical operations, merger, acquisition and restructuring activities. She began as one of the earlier employees of Genentech. 

Michael Ballenger specializes in Board of Director, CEO searches as well as officer-level assignments in research, product development and all business functions. He has 23 years of experience in executive search in all segments of the life science/healthcare product industry and has focused his last 10 years on work with start-up and development stage companies. He was previously the Managing Partner of Highland Partner's San Francisco office where he built the company's first Life Science/Healthcare Products Practice and was also Sr. Director of Human Resources for Genentech.

Lunch provided, but space is limited so please reserve a seat at http://www.acteva.com/booking.cfm?bevaID=197756

Grantwriting 101 including SBIR and STTRs

Grantwriting 101 including SBIR and STTRs

qed@qb3 - UCB Friday, February 5, 2010 12:00 to 1:00 pm Stanley Hall Room 621

SBIR/STTR grants can provide the critical funding necessary to launch your company.  But success requires mastering the tricks of the SBIR/STTR program, some of which have frustrated excellent groups.  From where to register to uploading your proposal, we'll cover the ins and outs of preparing grants for the NIH.  This seminar is aimed at new and experienced grantwriters, from academia and industry. Even veteran grantwriters will benefit from a review of the new formats required as of January 2010. 

Shauna Farr-Jones has a 10-year record of writing successful government grant and contract proposals on diverse life science topics, providing strategic input on both research and business plans. She has helped companies secure over $125 million in grant and contract funding from government and philanthropic agencies. Previously, she was at BioCentury Publications, where she analyzed the biotechnology industry. She was a postdoc in PharmChem at UCSF after a Ph.D. in Biochem from Tufts.  

Amy F. Boggs is an independent consultant with more than 8 years experience in grant-writing. She also handles the preparation of technical reports, INDs and NDAs, technology assessment, strategic research planning, and competitive landscaping. Prior, Dr. Boggs worked at Microcide and at IntraBiotics, where she managed an interdisciplinary technology in-licensing team. Dr. Boggs is an inventor on three issued patents and has worked on IND-enabling projects. She completed a Ph.D. in PharmChem at UCSF under Dr. Agard.

Lunch provided, but space is limited so please reserve a seat at http://www.acteva.com/booking.cfm?bevaID=197134  

Secrets of NIH SBIR and STTR grant applications

Angel Investment in High-Tech

Angel Investment in High-Tech

qed@qb3 - UCB Friday, January 8, 2010 12:00 to 1:00 pm Stanley Hall Room 621

The Value of Versatility for an Engineer Leading a Startup

The Value of Versatility  for an Engineer Leading a Startup

qed@qb3 - UCSF Thursday, January 7, 2010 12:00 to 1:00 pm Byers Room 212